Member of the DMC responsible for the safety of the PRIMUS-001 clinical trial "An adaptive phase II study of FOLFOX-A (FOLFOX and nab-paclitaxel) versus AG (nabpaclitaxel and gemcitabine) in patients with metastatic pancreatic cancer, with integrated biomarker evaluation"